The American Brachytherapy Society consensus statement for electronic brachytherapy.


Journal

Brachytherapy
ISSN: 1873-1449
Titre abrégé: Brachytherapy
Pays: United States
ID NLM: 101137600

Informations de publication

Date de publication:
Historique:
received: 15 10 2018
accepted: 31 10 2018
pubmed: 1 12 2018
medline: 18 12 2019
entrez: 1 12 2018
Statut: ppublish

Résumé

Brachytherapy is utilized in the treatment of many different malignancies; although traditionally performed with low-dose-rate or high-dose-rate techniques, more recently, electronic brachytherapy (EB) has emerged as a potential alternative. At this time, there are no evidence-based guidelines to assist clinicians in patient selection for EB and concerns exits regarding differences in dosimetry as compared to traditional brachytherapy techniques. As such, the American Brachytherapy Society appointed a group of physicians and physicists to create a consensus statement regarding the use of EB. Physicians and physicists with expertise in brachytherapy created a site-directed consensus statement for appropriate patient selection and utilization of EB based on a literature search and clinical experience. EB has been utilized to deliver accelerated partial breast irradiation with, thus far acceptable local control and toxicity rates including a randomized trial that used EB to deliver intraoperative radiotherapy; however, prospective data with large patient numbers and long-term follow up are needed. Increasing numbers of patients have been treated with EB for nonmelanomatous skin cancers; although, preliminary data are promising, there is a lack of data comparing EB to traditional radiotherapy techniques as well as a lack of long-term follow up. For treatment of the vaginal cuff with EB, small retrospective studies have been reported without long-term follow up. In light of a randomized trial in breast showing higher rates of recurrence and the lack of prospective data with mature follow up with other sites, as well as concerns regarding dosimetry, it is not recommended that EB be utilized for accelerated partial breast irradiation, nonmelanomatous skin cancers, or vaginal cuff brachytherapy outside prospective clinical trials at this time.

Identifiants

pubmed: 30497939
pii: S1538-4721(18)30673-1
doi: 10.1016/j.brachy.2018.10.006
pii:
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

292-298

Informations de copyright

Copyright © 2018 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Martin C Tom (MC)

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.

Jaroslaw T Hepel (JT)

Department of Radiation Oncology, Brown University, Providence, RI; Department of Radiation Oncology, Tufts University School of Medicine, Boston, MA.

Rakesh Patel (R)

Department of Radiation Oncology, Sutter Health, Los Gatos, CA.

Mitchell Kamrava (M)

Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA.

Shahed N Badiyan (SN)

Department of Radiation Oncology, Washington University, St Louis, MO.

Gil'ad N Cohen (GN)

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY.

Chirag Shah (C)

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH. Electronic address: csshah27@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH